Physicians disagree with acetaminophen restrictions
This article was originally published in The Tan Sheet
Executive Summary
A large majority -- 82 percent -- of recently surveyed physicians does not agree that FDA should pull acetaminophen products off the market. HCD Research surveyed 589 physicians July 17-19 after a joint advisory panel recommended FDA remove prescription acetaminophen products from the market, but said OTC combo products could stay. It also advised the agency restrict the amount of acetaminophen in OTC tablets and lower the dose (1"Health News Daily" July 1, 2009). While 86 percent of the physicians said the panel's recommendation will not change whether they will continue prescribing acetaminophen Rx drugs or recommending OTC drugs for their patients, nearly a third -- 29 percent -- said they are more likely to discuss warnings and dosage instructions with patients who use acetaminophen products, Flemington, N.J.-based HCD said July 20
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.